Page 5 - Revised January News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Rigel Announces U S FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

/PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the U.S. Food and Drug Administration (FDA) has approved REZLIDHIA™.

United statesSouth san franciscoCecilf whitaker jrDavid rosenRaul rodriguezJorgee cortesRigel pharmaceuticals incForma therapeutics incDrug administrationExchange commissionPrnewswire rigel pharmaceuticals incGeorgia cancer centerEuropean medicines agencyAmerican cancer societyScholar chairForma therapeutics

Rigel Announces U S FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Announces U S FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesSouth san franciscoCecilf whitaker jrDavid rosenRaul rodriguezJorgee cortesRigel pharmaceuticals incForma therapeutics incDrug administrationExchange commissionPrnewswire rigel pharmaceuticals incGeorgia cancer centerEuropean medicines agencyAmerican cancer societyScholar chairForma therapeutics

Rigel Announces Publication of Early Clinical Data of Olutasidenib in The Lancet Haematology

/PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the publication of data in The Lancet Haematology, which summarizes the Phase 1.

United statesSouth san franciscoDavid rosenWolfgang dummerRigel pharmaceuticals incLeukemia lymphoma societyForma therapeutics incDrug administrationExchange commissionEuropean medicines agencyAmerican cancer societyRigel pharmaceuticalsLancet haematologyForma therapeuticsNew orleansNew drug application

Rigel Announces Five Poster Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and Exposition

/PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the upcoming presentation of five posters highlighting data from the Company s.

United statesSouth san franciscoCecilf whitaker jrVadimv markovtsovDavid rosenMehdim moeziRaul rodriguezDavidj kuterJorgee cortesVickie mcdonaldHematology am soc hematol educ programConsultant haematologist at barts healthAmerican society of hematologyPrnewswire rigel pharmaceuticals incRigel pharmaceuticalsGeorgia cancer center

Rigel Reports Third Quarter 2022 Financial Results and Provides Business Update

/PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter ended September 30, 2022, including sales of.

South san franciscoUnited statesDavid rosenRaul rodriguezEli lillyHematology am soc hematol educ programUs department of defenseRigel pharmaceuticals incForma therapeutics incDrug administrationExchange commissionPrnewswire rigel pharmaceuticals incEuropean medicines agencyRigel pharmaceuticalsAmerican cancer societyForma therapeutics